Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Fredrick Ogugua

Hospitalist Plano, TX Medical Doctor

NPI 1609339902 CMS profile 11422102

1100 Allied Dr, Plano, TX 75093

Open in the dashboard

General payments

$6,145

150 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Fredrick Ogugua of Plano, TX is reported in the CMS Open Payments database as having received $6,145 across 150 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Hospitalist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,382 48
2024 General $2,440 75
2023 General $1,301 26
2022 General $21 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Fredrick Ogugua
  • Hospitalist median
  • Middle half of Hospitalist
  • National median

In program year 2025, general payments to Fredrick Ogugua were reported at $2,382. Among 6,882 Hospitalist profiles paid that year, the median was $86 and the middle half received between $30 and $191.

Show as a table
Year Fredrick Ogugua Hospitalist median Middle half National median
2019 $0 $96 $28–$201 $163
2020 $0 $48 $19–$125 $114
2021 $0 $70 $23–$167 $132
2022 $21 $85 $27–$174 $149
2023 $1,301 $89 $30–$191 $160
2024 $2,440 $95 $29–$204 $164
2025 $2,382 $86 $30–$191 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Boston Scientific Corporation $646 12 payments
  2. Novartis Pharmaceuticals Corporation $643 30 payments
  3. Abiomed $640 9 payments
  4. Medtronic, Inc. $540 12 payments
  5. Abbott Laboratories $477 6 payments
  6. Edwards Lifesciences Corporation $451 5 payments
  7. Pfizer Inc. $329 12 payments
  8. Inari Medical, Inc. $275 2 payments
  9. Sanofi-Aventis U.S. LLC $243 2 payments
  10. Chiesi USA, Inc. $238 4 payments
  11. Other $1,663 56 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $5,531 146 payments
  2. Education $613 4 payments
Products named General payments · program years 2022–2025
  1. LEQVIO $612 28 payments
  2. SAPIEN 3 Ultra RESILIA $433 4 payments
  3. VYNDAQEL $329 12 payments
  4. General - Vascular Access $325 3 payments
  5. CT THROMBECTOMY SYSTEM KIT $275 2 payments
  6. FLOWTRIEVER CATHETER, S $275 2 payments
  7. KENGREAL $238 4 payments
  8. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $237 1 payment
  9. Impella $226 3 payments
  10. RESOLUTE ONYX $221 1 payment
  11. Other $2,751 92 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

128

Median for Student in an Organized Health Care Education/Training Program: 43

Drug cost

$32,141

Median for Student in an Organized Health Care Education/Training Program: $442

Branded share of claims

20.3%

Median for Student in an Organized Health Care Education/Training Program: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 26 $31,177
Ezetimibe Generic 12 $404
Carvedilol Generic 37 $225
Atorvastatin Calcium Generic 21 $212
Amlodipine Besylate Generic 32 $123

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 30,207 Part D prescribers listed as Student in an Organized Health Care Education/Training Program; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $357
$357 — —
VYNDAQEL
  • PFIZER INC. $226
$226 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $159
$159 26 —
XARELTO
  • Janssen Pharmaceuticals, Inc $97
$97 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $86
$86 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

150 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hospitalist in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record